Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

U.S. Population Reference Values for the Myelofibrosis Symptom Assessment Form

Robert Morlock, Andréa Martins Bayer, Amy Morlock, Monika Wroclawska, Chad Gwaltney

Blood (2024) 144 (Supplement 1): 2419.

https://doi.org/10.1182/blood-2024-210727

Published: 2024

Journal Articles

Epik-P2: A Phase 2 Study of Alpelisib (ALP) in Pediatric and Adult Patients (pts) with PIK3CA -Related Overgrowth Spectrum (PROS)

Guillaume Canaud, Juan Carlos López-Gutiérrez, Adrienne M Hammill, Lisa Weibel, Séverine Niglis, Michaela Paul, Athanasia Papadimitriou, Monika Wroclawska, Denise M Adams

Blood (2024) 144 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2024-198497

Published: 2024

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-140408

Published: 2020

Journal Articles

Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Monika Wroclawska, MD, Tuochuan Dong, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2947.

https://doi.org/10.1182/blood-2019-128101

Published: 2019

Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Blood (2018) 132 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2018-99-115129

Published: 2018

Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Blood (2011) 118 (21): 3976.

https://doi.org/10.1182/blood.V118.21.3976.3976

Published: 2011

NARROW

U.S. Population Reference Values for the Myelofibrosis Symptom Assessment Form

Epik-P2: A Phase 2 Study of Alpelisib (ALP) in Pediatric and Adult Patients (pts) with PIK3CA -Related Overgrowth Spectrum (PROS)

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Email alerts

ASH Publications

American Society of Hematology

U.S. Population Reference Values for the Myelofibrosis Symptom Assessment Form

Epik-P2: A Phase 2 Study of Alpelisib (ALP) in Pediatric and Adult Patients (pts) with PIK3CA -Related Overgrowth Spectrum (PROS)

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only